Samsung Biologics will produce COVID-19 treatment once the US firm completed the development of the medicines.
Samsung Biologics will produce a treatment that can cure COVID-19 or coronavirus disease once the US firm completed the development of the medicines.
This, after Samsung Biologics won a USD 360-million contract to produce biopharmaceutical products from Nasdaq-listed Vir Biotechnology.
Seo Hae-su, the spokesperson of Samsung Biologics, said that the company agreed with a San Francisco-based startup to perform “large-scale” manufacturing services for the SARS-CoV-2 monoclonal antibody (mAb) program, adding that the monetary value of the said contract was estimated to USD 360 million.
Under the said agreement, Samsung Biologics as about to start its production in October 2020 and will start producing commercial batches in 2021 at its local plant in South Korea.
The partnership between Samsung Biologics and Vir Biotechnology came after South Korea President Moon Jae-in asked the country’s expanded role to develop vaccines and treatment for coronavirus disease or COVID-19.
What can you say about this? Just feel free to leave your reactions in the comment section.
Thank you for visiting our website. We hope we have helped you with regard to this matter. You may keep coming back for more informative guides.
For more news and updates, follow Philippine Newspaper on Facebook!